Rare Epileptic Encephalopathies
Zogenix International Limited focuses on clinical research in CDKL5 deficiency disorder, Dravet syndrome, and Lennox-Gastaut syndrome, with an emphasis on seizure-related conditions affecting both children and adults.
- CDKL5 deficiency disorder
- Dravet syndrome
- Lennox-Gastaut syndrome
The sponsor’s trial portfolio reflects interest in severe epilepsy and developmental epileptic encephalopathies that require ongoing therapeutic management.
Seizure Control and Symptom Management
Research activity is centered on treatment approaches for reducing seizure burden and improving control in patients with difficult-to-treat seizure disorders.
- Adjunctive therapy
- Seizure reduction
- Epileptic encephalopathy
The sponsor’s clinical interests include therapies intended to support patients with persistent convulsive symptoms across different age groups.
Pediatric and Adult Neurology
The funded studies include both pediatric and adult populations, indicating a therapeutic focus that spans the lifespan in rare neurological disease.
- Pediatric neurology
- Adult epilepsy care
- Rare neurological disorders
This area of interest includes long-term management needs in patients living with chronic seizure syndromes.
Long-term Safety and Tolerability
Clinical research also examines the safety and tolerability of fenfluramine-based treatment in rare seizure conditions, with attention to extended use in routine care settings.
- Long-term safety
- Tolerability
- Fenfluramine
These studies align with therapeutic needs in chronic antiepileptic management for patients with refractory seizures.
